-
2
-
-
0030905949
-
Guidelines for the diagnosis and management of migraine in clinical practice
-
Pryse-Phillips WEM, Dodick DW, Edmeads JG, et al. Guidelines for the diagnosis and management of migraine in clinical practice. Can Med Assoc J 1997; 156:1273-87.
-
(1997)
Can Med Assoc J
, vol.156
, pp. 1273-1287
-
-
Pryse-Phillips, W.E.M.1
Dodick, D.W.2
Edmeads, J.G.3
-
3
-
-
0030614987
-
1D) agonists and other agents in acute migraine
-
1D) agonists and other agents in acute migraine. Neurol Clin 1997;15:61-83.
-
(1997)
Neurol Clin
, vol.15
, pp. 61-83
-
-
Mathew, N.T.1
-
5
-
-
0032481904
-
Migraine
-
Ferrari MD. Migraine. Lancet 1998;351:1043-51.
-
(1998)
Lancet
, vol.351
, pp. 1043-1051
-
-
Ferrari, M.D.1
-
7
-
-
0001654075
-
A study to determine the absolute oral bioavailability of naratriptan
-
Abstract 07-A 15
-
Fuseau E, Baille P, Kempsford RD, et al. A study to determine the absolute oral bioavailability of naratriptan. Cephalalgia 1997;17:417. Abstract 07-A 15.
-
(1997)
Cephalalgia
, vol.17
, pp. 417
-
-
Fuseau, E.1
Baille, P.2
Kempsford, R.D.3
-
9
-
-
0030908742
-
Naratriptan: Biological profile in animal models relevant to migraine
-
Connor HE, Feniuk W, Beanie DT, et al. Naratriptan: Biological profile in animal models relevant to migraine. Cephalalgia 1997;17:145-52.
-
(1997)
Cephalalgia
, vol.17
, pp. 145-152
-
-
Connor, H.E.1
Feniuk, W.2
Beanie, D.T.3
-
11
-
-
0344865854
-
A study of the effect of subcutaneous naratriptan 1.5 mg on myocardial perfusion in migraineurs using positron emission tomography
-
Abstract 07-A 37
-
Camici P, Melin J, Gnecchi-Ruscone T, et al. A study of the effect of subcutaneous naratriptan 1.5 mg on myocardial perfusion in migraineurs using positron emission tomography. Cephalalgia 1997;17:424. Abstract 07-A 37.
-
(1997)
Cephalalgia
, vol.17
, pp. 424
-
-
Camici, P.1
Melin, J.2
Gnecchi-Ruscone, T.3
-
12
-
-
0343103886
-
The effects of subcutaneous naratriptan 1.5 mg on the systemic, pulmonary, and coronary circulation in patients with suspected coronary artery disease
-
Abstract 07-A 47
-
Swan L, Birnie DH, Hood S, et al. The effects of subcutaneous naratriptan 1.5 mg on the systemic, pulmonary, and coronary circulation in patients with suspected coronary artery disease. Cephalalgia 1997;17:428. Abstract 07-A 47.
-
(1997)
Cephalalgia
, vol.17
, pp. 428
-
-
Swan, L.1
Birnie, D.H.2
Hood, S.3
-
13
-
-
9844243943
-
Subcutaneous naratriptan (1 mg, 5 mg and 10 mg) has no effect on peripheral blood flow as measured by forearm blood flow
-
Abstract 07-A 40
-
Yogendran L, Boswell D, Winter P, et al. Subcutaneous naratriptan (1 mg, 5 mg and 10 mg) has no effect on peripheral blood flow as measured by forearm blood flow. Cephalalgia 1997;17:425. Abstract 07-A 40.
-
(1997)
Cephalalgia
, vol.17
, pp. 425
-
-
Yogendran, L.1
Boswell, D.2
Winter, P.3
-
14
-
-
0002198120
-
The safety, tolerability, pharmacodynamics and pharmacokinetics of naratriptan in healthy elderly subjects
-
Abstract 3-21-04
-
Kempsford R, Fuseau E, Moss J, Bryson P. The safety, tolerability, pharmacodynamics and pharmacokinetics of naratriptan in healthy elderly subjects. J Neurol Sci 1997;150(Suppl):S168. Abstract 3-21-04.
-
(1997)
J Neurol Sci
, vol.150
, Issue.SUPPL.
-
-
Kempsford, R.1
Fuseau, E.2
Moss, J.3
Bryson, P.4
-
15
-
-
0002198120
-
Naratriptan oral pharmacokinetics in migraine subjects
-
Abstract 1-21-09
-
Fuseau E, Webster C, Asgharnejad M, Huffman C. Naratriptan oral pharmacokinetics in migraine subjects. J Neurol Sci 1997;150(Suppl):S33. Abstract 1-21-09.
-
(1997)
J Neurol Sci
, vol.150
, Issue.SUPPL.
-
-
Fuseau, E.1
Webster, C.2
Asgharnejad, M.3
Huffman, C.4
|